Koszalka Paulina, Farrukee Rubaiyea, Mifsud Edin, Vijaykrishna Dhanasekaran, Hurt Aeron C
WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Department of Microbiology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia.
Influenza Other Respir Viruses. 2020 Jul;14(4):460-464. doi: 10.1111/irv.12725. Epub 2020 Feb 11.
Baloxavir marboxil is a novel endonuclease inhibitor licensed for treatment of otherwise healthy or high-risk individuals infected with influenza. Viruses with reduced baloxavir susceptibility due to amino acid substitutions at residue 38 of the PA have been detected in some individuals following treatment. Here, we describe a genotypic pyrosequencing method that can be used to rapidly screen circulating influenza A and B viruses for substitutions in the PA/I38 codon and to quantify mixed viral populations. This method is suitable for surveillance of baloxavir susceptibility and to analyse samples from hospitalised patients undergoing baloxavir treatment to aid in clinical decision making.
巴洛沙韦酯是一种新型的核酸内切酶抑制剂，已获许可用于治疗感染流感的健康个体或高风险个体。在一些个体接受治疗后，已检测到由于PA蛋白第38位氨基酸替换而对巴洛沙韦敏感性降低的病毒。在此，我们描述了一种基因分型焦磷酸测序方法，该方法可用于快速筛查循环中的甲型和乙型流感病毒PA/I38密码子的替换情况，并对混合病毒群体进行定量。该方法适用于监测巴洛沙韦的敏感性，并分析接受巴洛沙韦治疗的住院患者的样本，以辅助临床决策。
